Michel Afargan
Amministratore Delegato presso LifeWave Ltd.
Posizioni attive di Michel Afargan
Società | Posizione | Inizio | Fine |
---|---|---|---|
LifeWave Ltd.
LifeWave Ltd. Medical SpecialtiesHealth Technology LifeWave Ltd. engages in the development and manufacture of a medical device for the treatment of chronic wounds. The company was founded on May 24, 2000 and is headquartered in Petach-Tikva, Israel. | Amministratore Delegato | 01/11/2007 | - |
Direttore/Membro del Consiglio | 20/10/2010 | - |
Storia della carriera di Michel Afargan
Precedenti posizioni note di Michel Afargan
Società | Posizione | Inizio | Fine |
---|---|---|---|
Intec Pharma Ltd.
Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel. | Corporate Officer/Principal | 01/01/2007 | 01/01/2007 |
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Corporate Officer/Principal | - | - |
Israeli Consortium of Pharmalogica | Fondatore | - | - |
Corporate Officer/Principal | - | - |
Formazione di Michel Afargan
The Hebrew University of Jerusalem | Doctorate Degree |
Ben-Gurion University of the Negev | Graduate Degree |
Statistiche
Distribuzione geografica
Israele | 7 |
Posizioni
Corporate Officer/Principal | 3 |
Graduate Degree | 2 |
Director/Board Member | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
LifeWave Ltd.
LifeWave Ltd. Medical SpecialtiesHealth Technology LifeWave Ltd. engages in the development and manufacture of a medical device for the treatment of chronic wounds. The company was founded on May 24, 2000 and is headquartered in Petach-Tikva, Israel. | Health Technology |
Intec Pharma Ltd.
Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel. | Health Technology |
Israeli Consortium of Pharmalogica | |
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Borsa valori
- Insiders
- Michel Afargan
- Esperienza